Measure: Blood Tests That Change a Decision

What It Is

A blood panel is a set of measurements drawn from one sample, and its value depends almost entirely on which measurements are on it and why. A small, well-chosen set reads back things that change a decision: whether to lower a cholesterol particle, whether blood sugar is drifting, whether the kidneys are under strain before any symptom shows. A large, undirected set, the kind marketed as a full-body or executive panel, reads back dozens of numbers in people with no symptoms, most of which were never going to change anything and some of which trigger a chain of follow-up even when nothing is wrong. Telling the two apart is the whole task, and it costs nothing: there is no product to buy and no test to order here, only the markers the evidence supports measuring and the ones it does not. Each is graded at the strength the research supports.

How to Read a Result

1A Reference Range Is Not the Same as Optimal

A laboratory reference range is simply where most results from a broadly healthy sample fall, usually the middle 95 percent. It is not the level that carries the lowest risk, and it is not a hard line between well and unwell. LDL cholesterol sits well inside the reference range at levels that trials still show benefit from lowering, so a value can read as normal on the report and still call for action.

2One Value Is a Snapshot, Retest Before Acting

Blood markers vary from day to day and with the laboratory, the time, illness, hydration and the last meal. A single number that is mildly off is a reason to retest, not a diagnosis. Many markers, from CRP to a borderline glucose, can move enough between two mornings to cross a threshold, so the trend across repeats carries more meaning than any one draw.

3A Number Is a Marker, Not the Whole Person

A result gains its meaning from context: your age, symptoms, family history, the other markers and the direction it is moving. The same ferritin means one thing in a tired menstruating woman and another in a well older man. A number read alone, without the person around it, is where both false alarms and false reassurance come from.

How It Works

Most useful markers are indirect readings of a process you cannot see. LDL cholesterol and ApoB are two ways of reading the same population of fatty particles that lodge in artery walls: LDL cholesterol measures how much cholesterol those particles carry, while ApoB counts how many particles there are, since each one carries a single ApoB molecule. When someone has small, cholesterol-poor particles, common in insulin resistance and high triglycerides, the two numbers disagree, and the particle count is the better read of risk. The deeper picture of how lipids move and lodge sits on the cholesterol and lipids page.

Blood sugar markers work the same way. HbA1c reflects the fraction of hemoglobin with glucose bound to it, built up over the red cell lifespan, so it averages roughly the past two to three months in a single draw, without fasting. Fasting insulin, folded together with fasting glucose into a value called HOMA-IR, estimates how hard the body is working to keep glucose in check, and can shift before HbA1c or fasting glucose move. The machinery underneath these numbers, how insulin clears glucose and what happens when cells stop listening to it, is on the insulin and glucose page.

What Changed

The common advice was to test everything every year to catch problems early, on the intuition that more information is always safer. The better evidence has revised that in two directions at once. Broad, undirected panels in people without symptoms have been tested in large randomized trials, and offering them made no measurable difference to how long people lived or to death from cancer or heart disease; the extra tests found more to label and treat without a payoff in outcomes.

At the same time, a few specific markers turn out to be more decision-changing than they are given credit for. ApoB reads lipid risk better than the standard cholesterol number when the two diverge, and Lp(a), an inherited particle that needs measuring only once in a lifetime, identifies people carrying extra heart risk that the usual panel misses entirely. So the change is toward focus: a short list of markers that guide prevention, and restraint about the rest.

The Markers That Change a Decision

Heart and Lipids

Heart and lipid markers are the highest-value group, because the evidence here points to cause, not just correlation, and to actions that lower risk.

• LDL cholesterol is the anchor. Across 26 randomized trials in about 170,000 people, each 39 mg/dL (1.0 mmol/L) drop lowered heart attacks and strokes by about 22 percent, and genetic, epidemiological and trial evidence together show LDL helps drive arterial disease, not merely accompany it.
• ApoB refines that reading by counting particles, and is most informative when it disagrees with LDL.
• Lp(a) is the underused one: largely set by genetics, stable across life, and measured a single time to flag a risk the standard panel does not show.
• hs-CRP, a marker of low-grade inflammation, adds a modest, independent amount of information, best used to tip a decision near a threshold.
• Blood pressure is not a blood test, but it belongs in the same conversation as one of the most decision-changing numbers you can track, and reading it correctly at home matters more than almost any lifestyle change made in response. The self-measures page covers the technique and the high blood pressure page covers what moves it.

Blood Sugar and Metabolism

HbA1c is the core blood-sugar marker: one draw, no fasting, and a read on the past few months that flags diabetes and prediabetes early enough to act. Fasting glucose adds a same-morning snapshot. HOMA-IR, built from fasting insulin and glucose, is an earlier and softer signal of insulin resistance that can move before the others, though insulin assays are not well standardized, so it is read as a personal trend across repeats rather than against a fixed cut-off. Together these numbers describe where someone sits on the progression from healthy metabolism toward diabetes, which is where most lifestyle change acts. The continuous glucose monitoring page covers the wearable version of watching glucose, and where it helps and where it does not.

Inflammation

hs-CRP is the practical inflammation marker. It rises with any infection, injury or flare, so a value taken when someone is unwell reflects that illness and not their baseline, and it is repeated when well. Read at baseline, higher hs-CRP comes with somewhat higher cardiovascular risk, independent of the usual factors but modest in size. It sharpens a decision already near a threshold and does not settle one alone.

Organs, Thyroid and Iron

Four more tests are worth ordering when there is a reason to look:

• eGFR and urine albumin are two kidney tests, one from blood and one from urine. Each independently predicts long-term risk, and a normal eGFR alongside rising urine albumin still marks trouble, which is why both belong on the panel.
• Liver enzymes (ALT, AST) screen for liver strain, and one raised value is read in context, since on its own it means little.
• TSH is the right first test when symptoms suggest a thyroid problem, such as fatigue, weight change or cold intolerance; checking it routinely in people who feel well has a weaker case.
• Ferritin, read with a full blood count, is the best single test for iron deficiency, and its meaning depends heavily on the person: low ferritin in a menstruating woman with fatigue is a different signal from a value in a well older adult, and ferritin also rises with inflammation, which can mask a true deficiency.

What You Probably Do Not Need

One strategy has the clearest evidence against it: the panel sold as peace of mind, dozens of markers ordered at once in someone with no symptoms and no specific reason. Randomized trials of exactly this strategy, pooled across 17 studies and 251,891 people, found it left overall mortality and death from cancer and heart disease unchanged, while increasing the number of diagnoses and prescriptions.

The problem is not the accuracy of the tests. Most abnormal-looking results in a low-risk person are either meaningless variation or findings that would never have caused harm, and each one can lead a healthy person into further tests, scans and procedures that carry their own risk. This is the position captured in the Choosing Wisely campaign and in preventive-services reviews of routine screening: a test ordered for a reason is worth having, a test ordered because it was on the list usually is not.

A marker is worth measuring when a plausible result would change what you do. If no result would change anything, the test generates follow-up, not information.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Cholesterol And Lipids

Each 39 mg/dL (1.0 mmol/L) drop in LDL cholesterol cuts heart attacks and strokes about 22%Strong

In plain terms

The more you lower LDL cholesterol, the fewer heart attacks and strokes, and it does not matter much how you lower it. That is why LDL is the lipid number that guides a decision.

In detail

The Cholesterol Treatment Trialists pooled individual data from 26 statin trials totaling about 170,000 participants. Major vascular events fell by a proportional 22% (relative risk 0.78, 95% CI 0.76 to 0.80) for every 39 mg/dL (1.0 mmol/L) reduction in LDL cholesterol, and the relationship held across baseline risk and across the size of the reduction. Because the benefit scales with the absolute LDL drop, LDL is a marker that reads back a modifiable risk rather than a fixed characteristic.

Who this may not transfer to:Trials pooled men and women across many countries; the proportional benefit per unit of LDL lowering applies broadly to adults deciding how far to lower LDL.

The study · 1

Cholesterol Treatment Trialists Collaboration, efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials · Lancet 2010;376(9753):1670-1681

LDL cholesterol causes arterial disease, and the harm builds up over a lifetimeStrong

In plain terms

LDL is not just linked to heart disease, it helps drive it, and the damage builds up over a lifetime. A high number earlier in life matters more than the same number caught late.

In detail

The consensus panel drew on Mendelian randomization (people who inherit LDL-lowering gene variants have correspondingly lower lifetime cardiovascular risk), long-running cohorts, and randomized trials, and found all three lines converge on causation. The genetic data show the effect is a function of cumulative LDL exposure, area under the curve of concentration times time, which is why lowering LDL earlier yields more benefit per unit than lowering it late.

Who this may not transfer to:Genetic and trial evidence spans large mixed adult populations; the cumulative-exposure principle applies to anyone carrying a raised LDL earlier in life.

The study · 1

Ference et al., low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel · Eur Heart J 2017;38(32):2459-2472

Measurement And Diagnosis

Higher HbA1c predicted later diabetes and heart disease across 11,092 adults, from one drawStrong

In plain terms

HbA1c reflects your average blood sugar over the past few months in one draw, no fasting needed. A rising value flags diabetes risk early, while there is still time to act.

In detail

In the Atherosclerosis Risk in Communities study, 11,092 Black and White adults without diabetes had baseline HbA1c measured and were followed roughly 15 years. Higher HbA1c was associated in a graded way with diagnosed diabetes and with coronary heart disease, stroke and death, and for cardiovascular endpoints HbA1c was at least as informative as fasting glucose. HbA1c reflects glycation over the preceding two to three months, so unlike a fasting glucose it does not hinge on a single morning or on whether the person fasted.

Who this may not transfer to:The cohort was US Black and White adults without diabetes; HbA1c transfers as a fasting-free read of recent blood sugar, with the haemoglobin caveats noted.

The study · 1

Selvin et al., glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults · N Engl J Med 2010;362(9):800-811

eGFR below 60 and rising urine albumin each independently predict long-term death riskStrong

In plain terms

Two quiet tests, one from blood (eGFR) and one from urine (albumin), flag kidney trouble and higher risk of death long before symptoms appear. Together they tell you more than either does alone.

In detail

The Chronic Kidney Disease Prognosis Consortium pooled 14 general-population cohorts, about 105,872 participants. All-cause mortality rose once estimated GFR fell below 60 mL/min/1.73m2, and urine albumin-to-creatinine ratio was a continuous, independent predictor of all-cause and cardiovascular mortality across the range. Because eGFR and albuminuria capture different aspects of kidney damage, current staging uses both axes; a normal eGFR with rising albumin still marks added risk.

Who this may not transfer to:General-population cohorts of mixed-sex adults; eGFR and albumin transfer as long-term risk markers once confirmed on repeat testing.

The study · 1

Chronic Kidney Disease Prognosis Consortium (Matsushita et al.), association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis · Lancet 2010;375(9731):2073-2081

Broad health checks left death unchanged across 251,891 people (risk ratio 1.00)Strong · no effect

In plain terms

Handing healthy people a broad checkup of many tests did not help them live longer or avoid death from cancer or heart disease. Finding more things did not translate into better outcomes.

In detail

The Cochrane review pooled 17 randomized trials, 251,891 participants, comparing general health checks (multiple screening tests and risk-factor measurements) against usual care in unselected adults. All-cause mortality was unchanged (risk ratio 1.00, 95% CI 0.97 to 1.03) on high-certainty evidence, as were cancer and cardiovascular mortality. The checks did increase the number of diagnoses and prescriptions, so more was found and treated without a measurable payoff in death or disease. The finding is about broad, undirected panels in people without symptoms, not about a specific test ordered for a specific reason.

Who this may not transfer to:Trials enrolled unselected mixed-sex adults; the no-effect result applies to broad routine screening of the well, not to a targeted test ordered for a reason.

The study · 1

Krogsboll et al., general health checks in adults for reducing morbidity and mortality from disease · Cochrane Database Syst Rev 2019;(1):CD009009

ApoB, the particle count, reads cardiovascular risk better than LDL cholesterolModerate

In plain terms

ApoB counts how many artery-clogging particles you carry, not just how much cholesterol is in them. When the two disagree, the particle count is the better guide to risk, and it is still ordered too rarely.

In detail

Sniderman and colleagues pooled studies comparing lipid markers and found ApoB outperformed both LDL cholesterol and non-HDL cholesterol as a predictor of cardiovascular events. Marston and colleagues, analyzing UK Biobank participants, found the risk of myocardial infarction tracked the concentration of ApoB-containing particles rather than their cholesterol or triglyceride content; once ApoB was accounted for, the associations of LDL cholesterol and triglycerides largely fell away. ApoB is most useful when it diverges from LDL cholesterol, as it often does in insulin resistance, high triglycerides or diabetes.

Who this may not transfer to:Marker-comparison studies and the UK Biobank cohort are mixed-sex adults; the particle-count advantage matters most in insulin resistance, high triglycerides or diabetes.

The studies · 2

Sniderman et al., a meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk · Circ Cardiovasc Qual Outcomes 2011;4(3):337-345

Marston et al., association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis · JAMA Cardiol 2022;7(3):250-256

Each 3.5-fold higher Lp(a) carries about 1.13 times the coronary risk, and it is inherited so you measure it onceModerate

In plain terms

Lp(a) is a cholesterol particle you are mostly born with. A high level adds heart risk on top of your other numbers, and because it barely changes through life you only need it measured once.

In detail

The Emerging Risk Factors Collaboration pooled individual data from about 126,000 participants in long-term prospective studies and found lipoprotein(a) associated continuously with coronary heart disease and stroke, a relative risk near 1.13 (95% CI 1.09 to 1.18) per 3.5-fold higher concentration after adjustment for conventional risk factors. Genetic work found LPA gene variants that raise lipoprotein(a) are associated with coronary disease, which supports a causal reading. Levels are roughly 90% heritable and stable across adulthood, so a single measurement classifies a person for life.

Who this may not transfer to:Pooled cohorts and genetic data are mixed-sex adults; because Lp(a) is inherited, one measurement carries across a person's adult life.

The studies · 2

Emerging Risk Factors Collaboration, lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality · JAMA 2009;302(4):412-423

Clarke et al., genetic variants associated with Lp(a) lipoprotein level and coronary disease · N Engl J Med 2009;361(26):2518-2528

Each standard deviation higher hs-CRP adds about 1.23 times the coronary risk after full adjustmentModerate

In plain terms

hs-CRP is a general measure of low-grade inflammation, and higher levels come with somewhat higher heart risk. It refines the picture at the margins and is not used on its own.

In detail

The Emerging Risk Factors Collaboration pooled individual records from 160,309 people without a history of vascular disease. The age- and sex-adjusted risk ratio for coronary heart disease was 1.63 (95% CI 1.51 to 1.76) per 1-SD higher log C-reactive protein, attenuating to 1.37 (1.27 to 1.48) after adjustment for conventional risk factors and to 1.23 (1.07 to 1.42) after further adjustment for fibrinogen. The independent contribution is modest, which is why hs-CRP is used to reclassify people near a decision threshold rather than as a primary screen.

Who this may not transfer to:Pooled cohorts of mixed-sex adults without prior vascular disease; the modest independent signal transfers as a refiner near a decision threshold.

The study · 1

Emerging Risk Factors Collaboration, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis · Lancet 2010;375(9709):132-140

Evidence is insufficient to recommend thyroid screening in symptom-free adults, while TSH is the first test once symptoms appearModerate · mixed

In plain terms

There is no strong case for checking thyroid in people who feel fine. When symptoms point to the thyroid, TSH is the right first test.

In detail

The Task Force reviewed screening asymptomatic, non-pregnant adults for thyroid dysfunction and issued an I statement, concluding the evidence was insufficient to assess the balance of benefits and harms, largely because subclinical abnormalities are common, often resolve, and treating them in people without symptoms has not shown clear benefit. This is a statement about screening the well, not about diagnosis: in someone with fatigue, weight change, cold intolerance or other suggestive features, TSH with reflex free T4 is the standard first-line test.

Who this may not transfer to:The verdict covers asymptomatic non-pregnant adults; pregnancy and symptomatic testing are separate situations it does not cover.

The study · 1

LeFevre, US Preventive Services Task Force, screening for thyroid dysfunction: US Preventive Services Task Force recommendation statement · Ann Intern Med 2015;162(9):641-650

HOMA-IR, from fasting insulin and glucose, gives an early read on insulin resistanceEmerging

In plain terms

Fasting insulin, combined with fasting glucose into a value called HOMA-IR, can hint that your body is working harder to control blood sugar before the usual tests change. It is a useful early clue rather than a settled test.

In detail

HOMA-IR is derived as fasting insulin times fasting glucose divided by a constant, a model calibrated to the hyperinsulinemic-euglycemic clamp. It correlates reasonably with clamp-measured insulin resistance and can rise while HbA1c and fasting glucose are still normal, which is what makes it appealing as an early signal. Its limits are practical: insulin assays are not well standardized between laboratories, day-to-day variation in fasting insulin is wide, and there is no single agreed cut-off, so it is read as a trend and a rough band rather than a precise threshold.

Who this may not transfer to:Derived from a model calibrated to clamp studies; read as a personal trend over time rather than compared against a fixed cut-off between people.

The study · 1

Wallace, Levy and Matthews, use and abuse of HOMA modeling · Diabetes Care 2004;27(6):1487-1495

Evidence is insufficient to recommend vitamin D screening in symptom-free adultsEmerging · mixed

In plain terms

Routinely checking vitamin D in people who feel well is not clearly worth it. The evidence is not there yet, and experts do not even agree on the level that counts as low.

In detail

In its 2021 recommendation the US Preventive Services Task Force found insufficient evidence (an I statement) to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic, community-dwelling, non-pregnant adults. A core difficulty is that there is no consensus cut-off for deficiency, so the same person can be labeled deficient or replete depending on the laboratory, and trials of screening-and-treating in unselected adults have not shown clear health benefit. Testing remains reasonable when there is a specific reason, such as a condition or medication affecting vitamin D.

Who this may not transfer to:The verdict covers asymptomatic community-dwelling non-pregnant adults; it does not extend to people with a specific reason to test.

The study · 1

US Preventive Services Task Force, screening for vitamin D deficiency in adults: US Preventive Services Task Force recommendation statement · JAMA 2021;325(14):1436-1442

Go Deeper

• Continuous glucose monitoring: the wearable version of watching blood sugar, where it changes outcomes and where the marketing goes beyond the evidence.
• Self-measures: what you can test at home without a blood draw, including how to read blood pressure correctly, and what each measure predicts.
• Insulin and glucose: the physiology behind HbA1c, fasting glucose and HOMA-IR, and what insulin resistance actually is.
• Cholesterol and lipids: a fuller reading of the lipid panel, why LDL and ApoB carry the risk, and what moves them.

The Chinese Medicine View

Chinese medicine has no blood marker and does not reach for one, and forcing its categories onto a lab report does justice to neither. What it offers is a different unit of analysis. Where a panel isolates one variable at a time, the tradition reads a pattern, drawing many signs into a picture of a whole person in a particular state:

• tongue and pulse
• complexion and sleep
• digestion, temperature, and energy through the day

A single sign read alone is treated as a fragment, and the classical texts are explicit that one finding out of context can mislead, which matches the modern caution that one abnormal value is not a diagnosis.

The tradition also holds the distinction between root and branch, ben and biao. A number on a report is usually a branch, a manifestation, and the questions a practitioner asks reach for the root behind it: the constitution and the imbalance producing the reading, and why this person in this season shows it. The two frames answer different questions and are strongest kept side by side. A lipid particle count and a diagnosis of, say, Spleen failing to transform Dampness are not translations of one another, and neither confirms the other; each is a way of deciding what to do, from a different angle, about the same person.

Cautions For This Practice

Extra restraint

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

A borderline or incidental result sets off cascades of more testing, harm reported by 991 physicians

Ganguli and colleagues surveyed a national sample of 991 US physicians about cascades of care following incidental findings. Almost all had experienced them, and majorities reported resulting harms including physical harm from downstream procedures, psychological harm and anxiety for patients, wasted time and financial cost, and personal frustration. The more markers a panel measures in a person with no symptoms, the more borderline and incidental results it produces, and each one can start a cascade that carries its own risks independent of whether a real problem existed.Ganguli et al., cascades of care after incidental findings in a US national survey of physicians

Read Results With a Clinician Who Knows Your History

The markers here gain their meaning from your age, symptoms, family history and the other numbers alongside them. A result is information for a conversation with a clinician who has your full picture, not a verdict to reach on your own.

One Abnormal Value Is Not a Diagnosis

Blood markers vary between days, laboratories and circumstances. A single value sitting a little outside the range is a reason to repeat it before drawing any conclusion, and a diagnosis rests on repeated measurements read in context, not on one surprising number.

Do Not Change Treatment Off a Single Number

A home or one-off reading is a prompt to ask a question, not a basis for starting, stopping or adjusting a medication. Take the results and the trend to a prescriber before acting on a value alone.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Which blood tests are actually worth getting?

The short list is the one whose results would change a decision. For heart risk that means a lipid panel, ApoB where it can be had, and Lp(a) once in a lifetime; hs-CRP refines the picture near a decision point. For metabolism it means HbA1c and fasting glucose, with fasting insulin and HOMA-IR as an earlier signal. Kidney function through eGFR and urine albumin, and thyroid through TSH when symptoms suggest it, round out the set that guides real action. Blood pressure, though not a blood test, belongs alongside them. Beyond that, added tests earn their place for a specific reason, not by default.

Do I need a full-body or executive blood panel every year?

The evidence does not support it for people without symptoms. Across 17 randomized trials and 251,891 participants, offering broad general health checks made no difference to overall mortality or to death from cancer or heart disease, while increasing diagnoses and prescriptions. A focused set of markers chosen for your age and risk, repeated at sensible intervals, carries the information; the dozens-of-tests annual panel mostly adds follow-up.

What is Lp(a), and why is it measured only once?

Lipoprotein(a) is an LDL-like particle whose blood level is roughly 90 percent inherited and stays remarkably stable across adult life. That is why one measurement classifies your risk for good. A high level adds cardiovascular risk on top of your other lipids and is independent of them, which makes it useful, and it is still ordered too rarely. There is not yet a widely approved treatment that lowers Lp(a) and is shown to change outcomes, so a high result is used to sharpen overall risk and to focus attention on the factors that can be changed.

My clinician will not order ApoB or Lp(a). Can I get them another way?

Yes. Both are available through direct-to-consumer lab testing, where you order and pay for the test yourself without a clinician's requisition, which is an option when your own clinician will not order a marker you have reason to want. Lp(a) in particular needs measuring only once, so a single self-ordered test settles it for life. Take any abnormal result back to a clinician who knows your history, since what you do about a high number is a decision to make together.

What is the difference between ApoB and LDL cholesterol?

They read the same population of particles two ways. LDL cholesterol measures how much cholesterol the particles carry; ApoB counts how many particles there are, since each carries one ApoB molecule. When someone has many small, cholesterol-poor particles, common in insulin resistance and high triglycerides, LDL cholesterol can look reassuring while the particle count is high. In that situation ApoB is the better guide to risk. Where the two agree, either number tells you the same thing.

My result came back slightly abnormal. Should I worry?

A single value a little outside the reference range is usually a reason to retest rather than a diagnosis, because markers vary with the day, the laboratory, hydration, recent illness and the last meal. Reference ranges describe where most people fall, not a hard line into disease. The sensible next step is to repeat the test, look at the trend, and read it with a clinician who knows your history and the rest of your numbers, before acting on one reading alone.